Randomized, Double-blinded Study of Treatment:Teriflunomide, in Radiologically Isolated Syndrome

PHASE3CompletedINTERVENTIONAL
Enrollment

125

Participants

Timeline

Start Date

September 25, 2017

Primary Completion Date

February 5, 2019

Study Completion Date

October 4, 2022

Conditions
Multiple Sclerosis
Interventions
DRUG

Teriflunomide 14 MG Oral Tablet [Aubagio]

1 tablet once a day

DRUG

Placebo Oral Tablet

1 tablet once a day

Trial Locations (23)

3010

Inselspital Bern, Bern

31000

CHU de Toulouse, Toulouse

33000

CHU de Bordeaux, Bordeaux

34000

CHRU de Montpellier, Montpellier

35000

CHU de Rennes, Rennes

35100

Ege University Medical Faculty, Izmir

59000

CHRU de Lille, Lille

67000

CHU de Strasbourg, Strasbourg

69677

Hospices Civils de Lyon, Lyon

75013

APHP - Hôpital La Pitié Salpêtrière, Paris

Unknown

CHU de Caen, Caen

CHU de Clermont-Ferrand, Clermont-Ferrand

CHU de Grenoble, Grenoble

CHU de Nantes, Nantes

CHU de Nîmes, Nîmes

CHU de Rouen, Rouen

Hacettepe University, Ankara

Mustafa Kemal University, Antakya

Uludag University School of Medicine, Bursa

Istanbul University, Istanbul

Kocaeli University School of Medicine, Kocaeli

Ondokuz Mayis University, Faculty of Medicine, Samsun

06000

CHU de Nice, Nice

All Listed Sponsors
collaborator

Genzyme, a Sanofi Company

INDUSTRY

lead

Centre Hospitalier Universitaire de Nice

OTHER

NCT03122652 - Randomized, Double-blinded Study of Treatment:Teriflunomide, in Radiologically Isolated Syndrome | Biotech Hunter | Biotech Hunter